{"id":"https://openalex.org/W4306152136","doi":"https://doi.org/10.1186/s13046-022-02511-1","title":"Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist","display_name":"Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist","alternate_titles":[],"publication_year":2022,"publication_date":"2022-10-14","ids":{"openalex":"https://openalex.org/W4306152136","doi":"https://doi.org/10.1186/s13046-022-02511-1","pmid":"https://pubmed.ncbi.nlm.nih.gov/36229853","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9563815"},"language":"en","primary_location":{"id":"doi:10.1186/s13046-022-02511-1","doi":"https://doi.org/10.1186/s13046-022-02511-1","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13046-022-02511-1","pdf_url":"https://jeccr.biomedcentral.com/counter/pdf/10.1186/s13046-022-02511-1","source":{"id":"https://openalex.org/S33781645","display_name":"Journal of Experimental & Clinical Cancer Research","issn_l":"0392-9078","issn":["0392-9078","1756-9966"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Experimental &amp; Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4306152136"],"child_works_count":1,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://jeccr.biomedcentral.com/counter/pdf/10.1186/s13046-022-02511-1","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083570443","display_name":"Yu Bai","orcid":"https://orcid.org/0009-0002-5830-7358","observed_orcids":["https://orcid.org/0009-0002-5830-7358"]},"institutions":[{"id":"https://openalex.org/I20231570","display_name":"Peking University","ror":"https://ror.org/02v51f717","country_code":"CN","type":"education","lineage":["https://openalex.org/I20231570"]},{"id":"https://openalex.org/I4405267919","display_name":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)","ror":"https://ror.org/051e0s018","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267919"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yu Bai","raw_affiliation_strings":["Biomed-X Center, Academy for Advanced Interdisciplinary Studies, Peking University, 100871, Beijing, China","Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biomed-X Center, Academy for Advanced Interdisciplinary Studies, Peking University, 100871, Beijing, China","institution_ids":["https://openalex.org/I20231570"]},{"raw_affiliation_string":"Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China","institution_ids":["https://openalex.org/I4405267919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110516399","display_name":"Xin Zhang","orcid":"https://orcid.org/0000-0001-6036-2685","observed_orcids":["https://orcid.org/0000-0001-6036-2685","https://orcid.org/0000-0003-0124-099X"]},"institutions":[{"id":"https://openalex.org/I4405267919","display_name":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)","ror":"https://ror.org/051e0s018","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267919"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xin Zhang","raw_affiliation_strings":["Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China","institution_ids":["https://openalex.org/I4405267919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100717377","display_name":"Jie Zheng","orcid":"https://orcid.org/0000-0002-3843-1418","observed_orcids":["https://orcid.org/0000-0002-3843-1418"]},"institutions":[{"id":"https://openalex.org/I4405267919","display_name":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)","ror":"https://ror.org/051e0s018","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267919"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jie Zheng","raw_affiliation_strings":["Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China","institution_ids":["https://openalex.org/I4405267919"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100383207","display_name":"Ziyi Liu","orcid":"https://orcid.org/0000-0002-5660-9187","observed_orcids":["https://orcid.org/0000-0002-5660-9187"]},"institutions":[{"id":"https://openalex.org/I4405267919","display_name":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)","ror":"https://ror.org/051e0s018","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267919"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Ziyi Liu","raw_affiliation_strings":["Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China","institution_ids":["https://openalex.org/I4405267919"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Zhenfan Yang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267919","display_name":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)","ror":"https://ror.org/051e0s018","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267919"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Zhenfan Yang","raw_affiliation_strings":["Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China","institution_ids":["https://openalex.org/I4405267919"]}]},{"author_position":"last","author":{"id":null,"display_name":"Xiaolin Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I20231570","display_name":"Peking University","ror":"https://ror.org/02v51f717","country_code":"CN","type":"education","lineage":["https://openalex.org/I20231570"]},{"id":"https://openalex.org/I4405267919","display_name":"Dizal (Jiangsu) Pharmaceutical Co., Ltd. (China)","ror":"https://ror.org/051e0s018","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405267919"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Xiaolin Zhang","raw_affiliation_strings":["Biomed-X Center, Academy for Advanced Interdisciplinary Studies, Peking University, 100871, Beijing, China. xiaolin.zhang@dizalpharma.com","Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China. xiaolin.zhang@dizalpharma.com","Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biomed-X Center, Academy for Advanced Interdisciplinary Studies, Peking University, 100871, Beijing, China. xiaolin.zhang@dizalpharma.com","institution_ids":["https://openalex.org/I20231570"]},{"raw_affiliation_string":"Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China. xiaolin.zhang@dizalpharma.com","institution_ids":["https://openalex.org/I4405267919"]},{"raw_affiliation_string":"Dizal Pharmaceuticals, 199 Liangjing Rd, Zhangjiang Hi-Tech Park, Pudong District, 201203, Shanghai, China","institution_ids":["https://openalex.org/I4405267919"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5110516399"],"corresponding_institution_ids":["https://openalex.org/I20231570","https://openalex.org/I4405267919"],"apc_list":{"value":3490,"currency":"USD","value_usd":3490},"apc_paid":{"value":3490,"currency":"USD","value_usd":3490},"fwci":3.2509,"has_fulltext":true,"cited_by_count":33,"citation_normalized_percentile":{"value":0.94397463,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":99},"biblio":{"volume":"41","issue":"1","first_page":"302","last_page":"302"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12827","display_name":"Biochemical and Molecular Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adenosine-a2a-receptor-antagonist","display_name":"adenosine A2A receptor antagonists","score":0.8960000276565552},{"id":"https://openalex.org/keywords/tumor-microenvironment","display_name":"tumor microenvironment","score":0.9810000061988831},{"id":"https://openalex.org/keywords/creb-phosphorylation","display_name":"CREB phosphorylation","score":0.9509999752044678},{"id":"https://openalex.org/keywords/t-cell-suppression","display_name":"T cell suppression","score":0.781000018119812},{"id":"https://openalex.org/keywords/dendritic-cell-maturation","display_name":"dendritic cell maturation","score":0.8960000276565552},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.8309999704360962},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.7200000286102295},{"id":"https://openalex.org/keywords/pharmacokinetics-pharmacodynamics","display_name":"pharmacokinetics/pharmacodynamics","score":0.6389999985694885}],"concepts":[{"id":"https://openalex.org/C2776991684","wikidata":"https://www.wikidata.org/wiki/Q190012","display_name":"Adenosine","level":2,"score":0.6488333940505981},{"id":"https://openalex.org/C2780252810","wikidata":"https://www.wikidata.org/wiki/Q1455316","display_name":"Immunosuppression","level":2,"score":0.5693289041519165},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.5555049180984497},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5131948590278625},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5113058090209961},{"id":"https://openalex.org/C67907053","wikidata":"https://www.wikidata.org/wiki/Q356147","display_name":"Adenosine receptor","level":4,"score":0.5084297060966492},{"id":"https://openalex.org/C1629964","wikidata":"https://www.wikidata.org/wiki/Q106950729","display_name":"CREB","level":4,"score":0.48267582058906555},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.46664193272590637},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.44177767634391785},{"id":"https://openalex.org/C2778491162","wikidata":"https://www.wikidata.org/wiki/Q3063865","display_name":"Adenosine A2A receptor","level":5,"score":0.4244082570075989},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.4216320514678955},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.34213757514953613},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3214893341064453},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.286312073469162},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.21922406554222107},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.06687477231025696},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.061361461877822876},{"id":"https://openalex.org/C86339819","wikidata":"https://www.wikidata.org/wiki/Q407384","display_name":"Transcription factor","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000082082","descriptor_name":"Immune Checkpoint Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000241","descriptor_name":"Adenosine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007165","descriptor_name":"Immunosuppression Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007166","descriptor_name":"Immunosuppressive Agents","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D016207","descriptor_name":"Cytokines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017362","descriptor_name":"Cyclic AMP Response Element-Binding Protein","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D043705","descriptor_name":"Receptor, Adenosine A2A","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D059016","descriptor_name":"Tumor Microenvironment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1186/s13046-022-02511-1","doi":"https://doi.org/10.1186/s13046-022-02511-1","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13046-022-02511-1","pdf_url":"https://jeccr.biomedcentral.com/counter/pdf/10.1186/s13046-022-02511-1","source":{"id":"https://openalex.org/S33781645","display_name":"Journal of Experimental & Clinical Cancer Research","issn_l":"0392-9078","issn":["0392-9078","1756-9966"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Experimental &amp; Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:36229853","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36229853","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of experimental & clinical cancer research : CR","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9563815","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9563815/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"J Exp Clin Cancer Res","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:5f0fb1722e7343708d1c7af4b29d1bd2","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/5f0fb1722e7343708d1c7af4b29d1bd2","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-12 (2022)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1186/s13046-022-02511-1","doi":"https://doi.org/10.1186/s13046-022-02511-1","is_oa":true,"landing_page_url":"https://doi.org/10.1186/s13046-022-02511-1","pdf_url":"https://jeccr.biomedcentral.com/counter/pdf/10.1186/s13046-022-02511-1","source":{"id":"https://openalex.org/S33781645","display_name":"Journal of Experimental & Clinical Cancer Research","issn_l":"0392-9078","issn":["0392-9078","1756-9966"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-scientific","cwts-core","doaj","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","oarl","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320256","host_organization_name":"BioMed Central","host_organization_lineage":["https://openalex.org/P4310320256","https://openalex.org/P4310319965"],"host_organization_lineage_names":["BioMed Central","Springer Nature"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Experimental &amp; Clinical Cancer Research","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4306152136.pdf","grobid_xml":"https://content.openalex.org/works/W4306152136.grobid-xml"},"referenced_works_count":46,"referenced_works":["https://openalex.org/W94173706","https://openalex.org/W1965781264","https://openalex.org/W1973437945","https://openalex.org/W1979019662","https://openalex.org/W1984727851","https://openalex.org/W2005542488","https://openalex.org/W2005717890","https://openalex.org/W2018557026","https://openalex.org/W2048859636","https://openalex.org/W2049209548","https://openalex.org/W2074235065","https://openalex.org/W2077814905","https://openalex.org/W2085596919","https://openalex.org/W2087038612","https://openalex.org/W2088856300","https://openalex.org/W2095596429","https://openalex.org/W2143007555","https://openalex.org/W2160141570","https://openalex.org/W2160144435","https://openalex.org/W2257520046","https://openalex.org/W2294313458","https://openalex.org/W2622554186","https://openalex.org/W2776143999","https://openalex.org/W2887210902","https://openalex.org/W2888235779","https://openalex.org/W2896442534","https://openalex.org/W2911263380","https://openalex.org/W2971798665","https://openalex.org/W2982536492","https://openalex.org/W2987822998","https://openalex.org/W3006772360","https://openalex.org/W3011632447","https://openalex.org/W3015241273","https://openalex.org/W3015689173","https://openalex.org/W3015851374","https://openalex.org/W3016534231","https://openalex.org/W3045994471","https://openalex.org/W3175798793","https://openalex.org/W3176649308","https://openalex.org/W3180036074","https://openalex.org/W3195685486","https://openalex.org/W3201494894","https://openalex.org/W4220663292","https://openalex.org/W4226262594","https://openalex.org/W4230291902","https://openalex.org/W4293788415"],"related_works":["https://openalex.org/W4281973779","https://openalex.org/W2739770219","https://openalex.org/W4236824182","https://openalex.org/W4389480881","https://openalex.org/W3152730126","https://openalex.org/W2955116623","https://openalex.org/W2887210902","https://openalex.org/W4401715188","https://openalex.org/W3012213271"],"abstract_inverted_index":{"BACKGROUND:":[0],"Adenosine":[1,116,336],"is":[2,459,483],"a":[3,30,101,138,176,299,358,396,460],"potent":[4],"immunosuppressant":[5],"whose":[6],"levels":[7,81],"in":[8,19,47,83,114,127,135,137,160,167,183,199,214,229,245,259,266,276,293,305,318,347,355,357,380,387,403,419,434,449,473,479],"the":[9,93,146,219,366,439],"tumor":[10,187,407],"microenvironment":[11],"(TME)":[12],"are":[13,59],"often":[14],"much":[15,75],"higher":[16],"than":[17],"those":[18],"normal":[20],"tissues.":[21],"Binding":[22],"of":[23,32,99,119,152,225,243,252,289,333,339,372,445,477],"adenosine":[24,80,255],"to":[25,36,144,325,364],"its":[26,264],"receptor":[27],"A2aR":[28,45,57,72,103,109,268,462,468],"activates":[29],"cascade":[31],"genes":[33],"and":[34,95,130,169,189,263,270,280,330,350,389,409],"leads":[35],"immunosuppression.":[37],"In":[38,218,438],"addition,":[39],"immune":[40,202,311,422],"checkpoint":[41,203,312,423],"blockage":[42],"markedly":[43],"increases":[44],"expression":[46],"T":[48,128,161,231,278,348,381,451],"cells,":[49,162,232,382,452],"which":[50,85,105,464],"could":[51],"dampen":[52],"their":[53,88],"anti-tumor":[54,132,181,192,287,352,401,412],"response.":[55],"Several":[56],"antagonists":[58,73],"under":[60],"clinical":[61,66,89,97,222,241,442],"development,":[62],"but":[63],"with":[64,201,234,247,307,421,454,481],"limited":[65],"benefit":[67],"reported":[68],"so":[69],"far.":[70],"These":[71],"showed":[74,180,400],"diminished":[76],"activity":[77],"at":[78],"high":[79,150,370],"found":[82,113,472],"TME,":[84],"may":[86],"explain":[87],"underperformance.":[90],"We":[91],"report":[92],"discovery":[94],"early":[96],"development":[98,242,476],"DZD2269,":[100],"novel":[102,461],"antagonist":[104,463],"can":[106,465],"fully":[107,466],"block":[108,467],"mediated":[110,469],"immunosuppression":[111,147,273,367,470],"commonly":[112,471],"TME.":[115,474],"stimulates":[117,337],"phosphorylation":[118,159,338,379],"cyclic":[120,340],"AMP":[121,341],"response":[122,342],"element":[123,343],"binding":[124,344],"protein":[125,345],"(CREB)":[126,346],"cells":[129,172,279,284,349,392],"inhibits":[131,351],"cytokine":[133,165,353,385],"secretion":[134,166,354,386],"PBMCs":[136,356],"dose-dependent":[139,359],"manner.":[140,360],"DZD2269":[141,179,197,244,253,290,361,399,417,458,478],"was":[142,198,212,227,257,274,362,418,432,447],"able":[143,363],"reverse":[145,365],"induced":[148,368],"by":[149,156,369,376],"concentrations":[151,371],"adenosine,":[153,373],"as":[154,298,302,304,374],"demonstrated":[155,375],"inhibiting":[157,377],"CREB":[158,378],"restoring":[163,383],"Th1":[164,384],"PBMCs,":[168,388],"stimulating":[170,390],"dendritic":[171,391],"(DCs)":[173,393],"maturation.":[174,394],"As":[175,395],"single":[177,300,397],"agent,":[178,398],"growth":[182,402],"multiple":[184,294,404],"syngeneic":[185,295,405],"mouse":[186,296,406],"models,":[188,408],"more":[190,410],"profound":[191,411],"effects":[193,288,413],"were":[194,291,414],"observed":[195,213,415,433],"when":[196,416],"combination":[200,306,420],"inhibitors,":[204,424],"radiotherapy,":[205,309,425],"or":[206,310,426],"chemotherapy.":[207,427],"A":[208,314,428],"good":[209,429],"PK/PD":[210,430],"relationship":[211,431],"these":[215,435],"animal":[216,436],"models.":[217,437],"phase":[220,315,440],"1":[221,316,441],"study,":[223,443],"downregulation":[224,444],"pCREB":[226,446],"detected":[228,448],"human":[230,277,450],"consistent":[233,453],"preclinical":[235,455],"prediction.":[236,456],"Our":[237],"data":[238],"support":[239],"further":[240],"patients":[246,480],"cancer.":[248],"METHODS:":[249],"The":[250,286],"selectivity":[251],"for":[254],"receptors":[256],"tested":[258],"engineered":[260],"cell":[261],"lines,":[262],"efficacy":[265],"blocking":[267],"signaling":[269],"reversing":[271],"adenosine-mediated":[272],"assessed":[275],"peripheral":[281],"blood":[282],"mononuclear":[283],"(PBMCs).":[285],"evaluated":[292],"models":[297],"agent":[301],"well":[303],"chemotherapy,":[308],"inhibitors.":[313],"study":[317],"healthy":[319],"volunteers":[320],"(NCT04932005)":[321],"has":[322],"been":[323],"initiated":[324],"assess":[326],"safety,":[327],"pharmacokinetics":[328],"(PK)":[329],"pharmacodynamics":[331],"(PD)":[332],"DZD2269.":[334],"RESULTS:":[335],"CONCLUSION:":[457],"Clinical":[475],"cancer":[482],"warranted":[484],"(NCT04634344).":[485]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4306152136","counts_by_year":[{"year":2026,"cited_by_count":9},{"year":2025,"cited_by_count":8},{"year":2024,"cited_by_count":12},{"year":2023,"cited_by_count":4}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2022-10-14T00:00:00"}
